Daniel M. Himmel received his M.S. from the University of Pittsburgh studying the electrophysiology of pancreatic beta cells and cardiac pacemaker cells. He began his career at Merck & Co., Inc. exploring ionic channels in excitable tissue (especially aortic smooth muscle), using patch clamp and whole-cell voltage clamp methods, and then served as a medical programming specialist, where he developed clinical SAS-based software to assist the FDA in reviewing clinical data for new drug applications (NDAs). He subsequently received a Ph. D. at Brandeis University in biophysics & structural biology and went on to Rutgers University to pursue early-stage drug discovery for development of anti-AIDS/HIV treatments. His work and publications spanned a variety of biomedical fields, including macromolecular X-ray crystallography, biochemistry, and computational chemistry, and included collaborations with Johnson & Johnson, Pfizer, and Merck. He has served as the primary acting editor for the International Tables for Crystallography Volume F (Second Edition) under the auspices of the International Union of Crystallography. More recently, he has generated medical writing deliverables covering a broad range of disease states, including oncology, various allergic disorders, heart failure, diabetes, and epilepsy. Deliverables have included manuscript content for publication in major research journals, as well as abstracts, posters, and oral presentation slide decks for congresses.
